This proposal will advance centi-poult-H5, a broadly protective vaccine to protect poultry from highly pathogenic avian influenza (hpai)
Active Cooperative Agreement Awarded Last action
- Award ID
- AP26VSSP0000C052
- Recipient
-
Centivax, Inc. UEI GDKVJMCM5KQ6
- Awarding agency
-
Animal and Plant Health Inspection Service
Department of Agriculture
- Obligated
- $1,999,929
Award facts
- Assistance listing
- 10.025 Plant and Animal Disease, Pest Control, and Animal Care
- Completion date 36% complete
- Place of performance
- South San Francisco, CA 94080, USA
Award details come from USAspending.gov.
About this award
The Department of Agriculture Animal and Plant Health Inspection Service awarded a $1.999929 million Cooperative Agreement to Centivax, Inc. on February 2, 2026, to advance CENTI-POULT-H5, a broadly protective vaccine against highly pathogenic avian influenza (HPAI) in poultry under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025).
The vaccine incorporates eight divergent H5N1 hemagglutinin antigens alongside a T-cell targeting construct containing conserved influenza T-cell epitopes, designed to induce broad protective immunity against diverse H5N1 strains without requiring reformulation for emergent variants. Over the two-year performance period ending February 1, 2028, Centivax will execute three objectives: evaluate scalable mass-administration methods in chickens, including in ovo injection, aerosol spray vaccination, and drinking water administration; conduct dose-finding studies to determine optimal vaccine dosing via the selected method; and evaluate protective efficacy in an H5N1 challenge study. Work is performed in South San Francisco, California. The project is conducted in collaboration with Dr. Daniel Perez at the College of Veterinary Medicine, University of Georgia, an expert in avian influenza pathogenesis and poultry vaccine development. Expected outcomes include a vaccine providing broad protection against diverse HPAI strains that potentially reduces virus transmission and improves current vaccination strategies, addressing severe economic losses in the U.S. poultry industry.
Description
Centi-poult-H5 is intended to be a safe, potent, and efficacious vaccine that provides broad immunity across currently endemic hpai H5 variants as well as potential future variants without requiring reformulation for emergent strains. Hpai continues to devastate poultry flocks, which has caused severe economic losses and threatens the security of the U.S. Poultry industry. Centivax will leverage its computational universal immunity platform to advance a highly-multivalent vaccine that incorporates eight divergent H5N1 hemagglutinin antigens alongside a t-cell targeting construct containing conserved influenza t-cell epitopes. This multivalent design is engineered to induce broad protective immunity against diverse H5N1 strains through centivax's innovative epitope focusing approach. Centivax has already demonstrated efficacy for this vaccine approach for influenza in several species including mice, rats, pigs, ferrets, cattle and human immune organoids. This project will be executed over a 2-year, $2M timeline with three objectives 1) evaluate scalable mass-administration methods of centi-poult-H5 vaccine in chickens, including in OVO injection, aerosol spray vaccination, and drinking water administration; 2) conduct dose-finding studies to determine the optimal centi-poult-H5 dose via TH e selected mass-administration method; and 3) evaluate protective efficacy of the optimized centi-poult-H5 vaccine dose in a H5N1 challenge study in chickens. Expected outcomes include a vaccine that provides broad protection against diverse hpai strains, potentially reduces virus transmission, and significantly improves current vaccination strategies. The project will be conducted in collaboration with DR. Daniel perez at the college of veterinary medicine, university of georgia, an expert in avian influenza pathogenesis and poultry vaccine development. Success will deliver an optimal method for mass vaccination with centi-poult-H5 in chickens and robust evidence of its broad safety and efficacy, where centivax will be able to rapidly deploy centi-poult-H5 upon completion of this project to improve hpai outcomes for the poultry industry. Beneficiaries include the U.S. Poultry industry, consumers facing high EGG and poultry prices, and government agencies responsible for hpai control. The vaccine will contribute to USDA's comprehensive strategy to curb hpai, protect the poultry industry and lower EGG prices.
Quick answers
Who received award AP26VSSP0000C052?
AP26VSSP0000C052 was awarded to Centivax, Inc. by Animal and Plant Health Inspection Service (Department of Agriculture) on February 2, 2026.
How much is award AP26VSSP0000C052 worth?
$1,999,929 has been obligated on AP26VSSP0000C052.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award